fda warning compounding semaglutide september 2025 warns telehealth providers over obesity drug marketing US FDA warns online vendors

Preconceptional and maternal obesity: epidemiology and health consequences

The potential bias in the treatment comparisons was mitigated by the matched double-blind placebo controls, but this could have been further improved with a double-dummy approach

Thats not a reason to dismiss it, but it is a reason to pursue it under physician oversight rather than on your own

The Mazdutide trial also demonstrated that dual agonists could reduce hepatic fat in obese Chinese patients (Ji et al., 2023)

However, the platform lacks advanced personalization tools such as image-based scalp analysis and does not emphasize scalp health beyond basic regrowth treatments